Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has introduced Gonax (Degarelix Acetate), a gonadotrophin-releasing hormone (GnRH)-receptor blocker, for subcutaneous injection to treat prostate cancer in Japan.
Subscribe to our email newsletter
Gonax is designed to inhibit the binding of GnRH, a hormone produced by the hypothalamus in the brain, to the specific receptors thereby restraining the testosterone production and finally controlling the prostate cancer growth.
The data obtained from Phase-III trial conducted abroad besides Phase I and Phase II studies conducted in Japan has formed the basis for filing a market authorization application.
The studies demonstrated that Gonax maintained the blood testosterone levels below castration from third day till the whole treatment period eliminating the testosterone flow.
Gonax also demonstrated a satisfactory safety profile in the studies.